Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Nov;52(11):807–811. doi: 10.1136/jcp.52.11.807

Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.

M L Yu 1, W L Chuang 1, S C Chen 1, Z Y Lin 1, M Y Hsieh 1, L Y Wang 1, W Y Chang 1
PMCID: PMC501590  PMID: 10690168

Abstract

AIM: To compare the performance characteristics and clinical application of two different technologies for quantifying serum hepatitis C virus (HCV) RNA levels. METHODS: HCV RNA was quantified by Amplicor HCV Monitor assay (Amplicor) and Quantiplex HCV RNA 2.0 assay (bDNA-2) in 119 sera from 107 HCV infected patients. RESULTS: Both assays had similar sensitivity (79.4% for Amplicor; 86.0% for bDNA-2), acceptable coefficients of variation (5.3% in Amplicor; 2.6% in bDNA-2), and good linearity (r2 > or = 0.98). There was a positive correlation between quantification values of both methods (r = 0.683, p < 0.001). The Amplicor values were on an average 1.76 log lower than bDNA-2 results. Male subjects and HCV genotype 1b were significantly associated with higher viral load determined by Amplicor, but not with viral load measured by bDNA-2. In 70 chronic HCV infected patients treated with interferon alfa, mean (SD) pretreatment viral load in 27 complete responders (3.47 (0.84) logs for Amplicor, 5.63 (0.58) for bDNA-2) was significantly lower than in non-responders (4.43 (1.01) logs for Amplicor, 6.10 (0.67) logs for bDNA-2; p < 0.001). Cut off points of 3.9 logs for Amplicor and 5.8 logs for bDNA-2 were determined to be the best for predicting response to interferon alfa, giving acceptable sensitivity (70.4%, 74.1%), specificity (72.1%, 65.1%), and accuracy (71.4%, 68.6%), respectively. CONCLUSIONS: Both the Amplicor and bDNA-2 assays are clinically useful methods for HCV RNA quantification and are reliable for predicting the outcome of treatment, despite differences in absolute quantification values and in the correlation between HCV genotypes and viral load.

Full text

PDF
807

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  2. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  3. Collins M. L., Zayati C., Detmer J. J., Daly B., Kolberg J. A., Cha T. A., Irvine B. D., Tucker J., Urdea M. S. Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem. 1995 Mar 20;226(1):120–129. doi: 10.1006/abio.1995.1199. [DOI] [PubMed] [Google Scholar]
  4. Detmer J., Lagier R., Flynn J., Zayati C., Kolberg J., Collins M., Urdea M., Sánchez-Pescador R. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol. 1996 Apr;34(4):901–907. doi: 10.1128/jcm.34.4.901-907.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DuBois D. B., Gretch D., dela Rosa C., Lee W., Fine J., Blagg C. R., Corey L. Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis. 1994 Nov;24(5):795–801. doi: 10.1016/s0272-6386(12)80673-1. [DOI] [PubMed] [Google Scholar]
  6. Hagiwara H., Hayashi N., Mita E., Takehara T., Kasahara A., Fusamoto H., Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993 Mar;104(3):877–883. doi: 10.1016/0016-5085(93)91025-d. [DOI] [PubMed] [Google Scholar]
  7. Hanley J. A., McNeil B. J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983 Sep;148(3):839–843. doi: 10.1148/radiology.148.3.6878708. [DOI] [PubMed] [Google Scholar]
  8. Hawkins A., Davidson F., Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol. 1997 Jan;35(1):187–192. doi: 10.1128/jcm.35.1.187-192.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hayashi J., Kishihara Y., Yoshimura E., Tani Y., Yamaji K., Ikematsu H., Ishiko H., Kashiwagi S. Relationship of genotype to level of hepatitis C viraemia determined by competitive polymerase chain reaction. J Infect. 1995 May;30(3):235–239. doi: 10.1016/s0163-4453(95)90785-8. [DOI] [PubMed] [Google Scholar]
  10. Kato N., Yokosuka O., Hosoda K., Ito Y., Ohto M., Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology. 1993 Jul;18(1):16–20. [PubMed] [Google Scholar]
  11. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  12. Lau J. Y., Davis G. L., Kniffen J., Qian K. P., Urdea M. S., Chan C. S., Mizokami M., Neuwald P. D., Wilber J. C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993 Jun 12;341(8859):1501–1504. doi: 10.1016/0140-6736(93)90635-t. [DOI] [PubMed] [Google Scholar]
  13. Lau J. Y., Davis G. L., Prescott L. E., Maertens G., Lindsay K. L., Qian K., Mizokami M., Simmonds P. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med. 1996 May 15;124(10):868–876. doi: 10.7326/0003-4819-124-10-199605150-00002. [DOI] [PubMed] [Google Scholar]
  14. Lau J. Y., Simmonds P., Urdea M. S. Implications of variations of "conserved" regions of hepatitis C virus genome. Lancet. 1995 Aug 12;346(8972):425–426. doi: 10.1016/s0140-6736(95)92786-7. [DOI] [PubMed] [Google Scholar]
  15. Okamoto H., Tokita H., Sakamoto M., Horikita M., Kojima M., Iizuka H., Mishiro S. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol. 1993 Nov;74(Pt 11):2385–2390. doi: 10.1099/0022-1317-74-11-2385. [DOI] [PubMed] [Google Scholar]
  16. Reichard O., Norkrans G., Frydén A., Braconier J. H., Sönnerborg A., Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998 Jan 10;351(9096):83–87. doi: 10.1016/s0140-6736(97)06088-1. [DOI] [PubMed] [Google Scholar]
  17. Smith D. B., Davidson F., Yap P., Brown H., Kolberg J., Detmer J., Urdea M., Simmonds P., International HCV Collaborati Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group. J Infect Dis. 1996 Mar;173(3):727–730. doi: 10.1093/infdis/173.3.727. [DOI] [PubMed] [Google Scholar]
  18. Smith D. B., Mellor J., Jarvis L. M., Davidson F., Kolberg J., Urdea M., Yap P. L., Simmonds P. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol. 1995 Jul;76(Pt 7):1749–1761. doi: 10.1099/0022-1317-76-7-1749. [DOI] [PubMed] [Google Scholar]
  19. Toyoda H., Nakano S., Kumada T., Takeda I., Sugiyama K., Osada T., Kiriyama S., Orito E., Mizokami M. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol. 1996 Apr;48(4):354–359. doi: 10.1002/(SICI)1096-9071(199604)48:4<354::AID-JMV9>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  20. Vandamme A. M., Van Laethem K., Liu H. F., Van Brussel M., Delaporte E., de Castro Costa C. M., Fleischer C., Taylor G., Bertazzoni U., Desmyter J. Use of a generic polymerase chain reaction assay detecting human T-lymphotropic virus (HTLV) types I, II and divergent simian strains in the evaluation of individuals with indeterminate HTLV serology. J Med Virol. 1997 May;52(1):1–7. [PubMed] [Google Scholar]
  21. Yu M. L., Chuang W. L., Lu S. N., Chen S. C., Wang J. H., Lin Z. Y., Hsieh M. Y., Wang L. Y., Chang W. Y. The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan. Kaohsiung J Med Sci. 1996 Nov;12(11):605–612. [PubMed] [Google Scholar]
  22. Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES